GOSS Company Profile and Key Details

Q: Who are the executives of GOSS?

Mr. Bryan GiraudoChief Operating Officer & Chief Financial OfficerMr. Mario OrlandoSenior Vice President of Commercial New Product PlanningMr. Faheem HasnainCo-Founder, Chief Executive Officer, Pres & ChairmanMr. Christian WaageExecutive Vice President of Technical Operations & Admin.Dr. Laura L. Carter Ph.D.Chief Scientific OfficerMr. Matt CravetsSenior Vice President of BiometricsMr. Jeff BoernekeGen. Counsel & Sec.Ms. Caryn L. PetersonExecutive Vice President of Regulatory AffairsDr. Richard Aranda M.D.Chief Medical OfficerMs. Deanna WeberSenior Vice President of HRDr. Lisa Elizabeth Nolan Ph.D.MD & Pres of Gossamer Bio Ireland

NASDAQ : GOSS

Gossamer Bio

$0.16

-0.0038-2.26%

At Close 4:00 PM

70.67

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Gossamer Bio, Inc. (GOSS) stock declined over -2.26%, trading at $0.16 on NASDAQ, down from the previous close of $0.17. The stock opened at $0.18, fluctuating between $0.16 and $0.18 in the recent session.

Stock Snapshot

0.168

Prev. Close

38.51M

Market Cap

0.16

Day Low

-0.21

P/E Ratio

-0.79

EPS (TTM)

-0.71

Cash Flow per Share

0.18

Open

234.55M

Number of Shares

0.1761

Day High

80.83%

Free Float in %

0.28

Book Value

11.5M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	0.18	0.18	0.16	0.16	11.61M
Jun 18, 2026	0.20	0.20	0.16	0.17	23.16M
Jun 17, 2026	0.16	0.19	0.16	0.18	22.85M
Jun 16, 2026	0.17	0.17	0.17	0.17	8.61M
Jun 15, 2026	0.17	0.18	0.17	0.17	16.58M
Jun 12, 2026	0.18	0.18	0.16	0.16	17.99M
Jun 11, 2026	0.16	0.18	0.15	0.18	22.59M
Jun 10, 2026	0.16	0.17	0.14	0.16	33.99M
Jun 09, 2026	0.17	0.17	0.15	0.16	13.1M
Jun 08, 2026	0.18	0.18	0.16	0.17	14.24M
Jun 05, 2026	0.18	0.18	0.17	0.18	13.17M
Jun 04, 2026	0.19	0.19	0.18	0.18	8.99M
Jun 03, 2026	0.20	0.20	0.18	0.19	11.96M
Jun 01, 2026	0.23	0.24	0.20	0.20	19.75M
May 29, 2026	0.21	0.23	0.20	0.23	13.18M
May 28, 2026	0.21	0.21	0.20	0.21	11.58M
May 27, 2026	0.23	0.23	0.20	0.22	16.06M
May 26, 2026	0.22	0.24	0.21	0.22	13.16M
May 22, 2026	0.20	0.21	0.20	0.21	12.67M
May 21, 2026	0.24	0.24	0.19	0.20	36.45M

Contact Details

San Diego, CA 92121

United States

https://www.gossamerbio.com 858 684 1300

About Company

Gossamer Bio, Inc. operates as a U.S.-based, clinical-stage biopharmaceutical company. Its primary objective is to discover, acquire, advance, and market novel therapeutic solutions, specifically addressing conditions within immunology, inflammatory diseases, and oncology. The company's pipeline highlights several key drug candidates: GB002: An inhaled small molecule designed to inhibit platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, currently being developed for pulmonary arterial hypertension. GB004: An oral, gut-targeted small molecule in development for treating inflammatory bowel disease. GB5121: An oral, irreversible covalent small molecule that targets Bruton's Tyrosine Kinase (BTK), intended for primary central nervous system lymphoma. GB7208: Another oral small molecule BTK inhibitor, under investigation for multiple sclerosis. To support its drug development initiatives, Gossamer Bio has forged strategic licensing partnerships. It holds agreements with Pulmokine, Inc. for the advancement and commercialization of GB002 and its associated backup compounds. Additionally, the company collaborates with Aerpio Pharmaceuticals, Inc. regarding GB004 and related chemical entities. Founded in 2015, the enterprise was initially known as FSG, Bio, Inc. before rebranding as Gossamer Bio, Inc. in 2017. Its corporate headquarters are situated in San Diego, California.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

The stock is currently mid-range between its 52-week high and low $0.14 and $3.87. With a market capitalization of about $38.51 million, Gossamer Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.00). Key stats such as the average daily volume over the past year has been around 11.43 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Gossamer Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Faheem Hasnain, the company employs approximately 144 people and listed since February 08, 2019. Gossamer Bio, Inc. operates as a U.S.-based, clinical-stage biopharmaceutical company.

Technical Performance

GOSS has shown sold momentum, gaining 3.17% over the past week and 18.72% over the past quarter, though year-to-date performance is down -16.13%. Short-term trend indicators are mixed aligned (SMA20 -79.24%, SMA50 -84.14%, SMA200 -82.17%). The stock’s 14-day RSI is 14.83 (weak momentum), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -89.61% below its high and over 21.38% above its low. Average 10-day trading volume of 16.56 million shares is slightly above the 3-month average of 12.02 million, indicating heightened recent market interest.

Valuation Metrics

Gossamer Bio, Inc. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.72 and a price-to-book ratio of -0.25 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.24, also above market averages.

Dividend & Fair Value

Gossamer Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.10. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Gossamer Bio, Inc. generated EPS of -$0.69 over the past year. Five-year average earnings growth is 40.29%. Wall Street analysts project EPS growth of 13.11% annually over the next five years. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.19. Next year's EPS is expected at $35.24. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 4 Buy ratings, 2 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $12.00 to $0.28. The high target offers 7400.0% upside. The low target suggests 75.0% downside. The mean target is $7.69. This offers 4706.25% upside. Gossamer Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 18, 2026, missed forecasts by 17.65%. The prior quarter beat by 42.86%. Over the last six quarters, Apple has recorded several small beats. These include -11.11% in May 15, 2025.

Shareholding & Insider Activity

Gossamer Bio, Inc. has 227.38 million shares outstanding. The public float is 183.80 million shares, elevated short interest at 8.78% of float. This equals 18.75 million shares. The short ratio is 7.01 days. Institutional investors hold 81.79% of the float. Insiders own 3.52%. Omega Fund V, L.P. holds 6.55 million shares, Hasnain Faheem has 5.41 million shares and Gujrathi Sheila has 4.05 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Gossamer Bio has not generated any revenue. Returns are negative, with ROA at -57.65% and ROE at -286.47%.
On valuation metrics, Gossamer Bio trades at a P/E of -0.22, P/S of 0.72 and P/B of -0.25. The current ratio is 2.20 and quick ratio is 2.20. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -16964.53 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -1.26, supported by a cash flow-to-debt ratio of -0.84.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Gossamer Bio posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $4.39M (margin 0.00%). Operating income was - $173.76M (margin 0.0%). Net income was- $179.82M (EPS - $1.18).
The company ended the quarter with $296.43M in cash and short-term investments, a total debt of $212.46M, and net debt of $180.36M. Total assets were $311.92M, with equity of $62.77M. Financials further reflected weakness, with operating cash flow of - $159.16M, free cash flow of - $159.16M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Gossamer Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -39.1%, with price expected at $0.10 by July 06, 2026, within a range of $0.06 to $0.14 3-Month Outlook: Projected rise of 1282.46%, reaching $2.27 by September 16, 2026, with a range of $2.11 to $2.39. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by June 22, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Gossamer Bio, Inc. (NASDAQ:GOSS) shares are down -16.13% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Gossamer Bio, Inc. trading at a premium to the broader market with a P/E of -0.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.02, suggesting 7220.34% upside. Our AI forecast model points to short-term weakness (-39.1% over two weeks), a medium-term rise (1282.46% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Gossamer Bio, Inc. (GOSS) stock price?

Gossamer Bio, Inc. (NASDAQ: GOSS) stock price is $0.16 in the last trading session. During the trading session, GOSS stock reached the peak price of $0.18 while $0.16 was the lowest point it dropped to. The percentage change in GOSS stock occurred in the recent session was -2.26% while the dollar amount for the price change in GOSS stock was - $0.00.

GOSS's industry and sector of operation?

The NASDAQ listed GOSS is part of Biotechnology industry that operates in the broader Healthcare sector. Gossamer Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GOSS?

Mr. Bryan Giraudo
Chief Operating Officer & Chief Financial Officer
Mr. Mario Orlando
Senior Vice President of Commercial New Product Planning
Mr. Faheem Hasnain
Co-Founder, Chief Executive Officer, Pres & Chairman
Mr. Christian Waage
Executive Vice President of Technical Operations & Admin.
Dr. Laura L. Carter Ph.D.
Chief Scientific Officer
Mr. Matt Cravets
Senior Vice President of Biometrics
Mr. Jeff Boerneke
Gen. Counsel & Sec.
Ms. Caryn L. Peterson
Executive Vice President of Regulatory Affairs
Dr. Richard Aranda M.D.
Chief Medical Officer
Ms. Deanna Weber
Senior Vice President of HR
Dr. Lisa Elizabeth Nolan Ph.D.
MD & Pres of Gossamer Bio Ireland

How GOSS did perform over past 52-week?

GOSS's closing price is 17.29% higher than its 52-week low of $0.14 where as its distance from 52-week high of $3.87 is -95.76%.

How many employees does GOSS have?

Number of GOSS employees currently stands at 144.

Link for GOSS official website?

Official Website of GOSS is: https://www.gossamerbio.com

How do I contact GOSS?

GOSS could be contacted at phone 858 684 1300 and can also be accessed through its website. GOSS operates from 3013 Science Park Road, San Diego, CA 92121, United States.

How many shares of GOSS are traded daily?

GOSS stock volume for the day was 11.5M shares. The average number of GOSS shares traded daily for last 3 months was 11.43M.

What is the market cap of GOSS currently?

The market value of GOSS currently stands at $38.51M with its latest stock price at $0.16 and 234.55M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	144
Beta	2
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GOSS Company Profile and Key Details

Gossamer Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways